Skip to content
BioMedomics Announces Grants, Starting on June 19th, 2024, the World Sickle Cell Day, to Advance Sickle Cell Disease Testing in Sub-Saharan Africa

BioMedomics, the manufacturer of Sickle SCAN, the world’s first Point of Care rapid test for Sickle Cell Disease (SCD), is excited to announce a Request for Proposals (RFP) for Independent Research Grant aimed at advancing the testing and management of Sickle Cell Disease (SCD) in Sub-Saharan African countries.

The grant program will take the course of three years, starting on June 19th, 2024, the world’s Sickle Cell Disease day.

This initiative is part of BioMedomics’ ongoing commitment to improving global health through innovative diagnostics and education.

Sickle SCAN is a revolutionary diagnostic tool that enables rapid, convenient and accurate testing for SCD at the point of care, empowering healthcare professionals to swiftly diagnose Sickle Cell Disease and facilitating timely intervention and personalized patient care.

The program aims to increase Sickle Cell Disease awareness and facilitate the availability and affordability of POCT testing in Sub-Saharan Africa. BioMedomics will partner with local distributors to implement the program.

Frank Wang, PhD, founder and CEO of BioMedomics, expressed his commitment to patients, stating “As the world’s leading manufacturer of hemoglobin subtype antibodies, such as hemoglobin A, hemoglobin C, hemoglobin E, hemoglobin F and hemoglobin S, we will continue to develop more diagnostic products to fight against Sickle Cell Disease. ”

Xingzhou Liu, MD, MBA, VP and Chief Commercial Officer of BioMedomics, emphasized the company’s commitment to expanding access to Sickle SCAN, “Our goal is to reach more patients in need, and generate more attention for SCD patients, the families and the community”. Liu continued, ”In addition, we continue to develop broader and stronger distribution network to make Sickle SCAN readily available to a wider audience, ultimately improving the lives of individuals affected by SCD.”

For more information, please refer to Grant RFP.